tiprankstipranks
Trending News
More News >

Hansoh Pharmaceutical Receives Approval for Clinical Trials of HS-10510 Tablets

Story Highlights
Hansoh Pharmaceutical Receives Approval for Clinical Trials of HS-10510 Tablets

Don’t Miss TipRanks’ Half-Year Sale

An update from Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) is now available.

Hansoh Pharmaceutical Group Company Limited announced that its self-developed innovative drug, HS-10510 tablets, has received Clinical Trial Approval from China’s National Medical Products Administration. This approval allows the company to proceed with clinical trials targeting primary hypercholesterolemia and mixed dyslipidemia, potentially strengthening its position in the pharmaceutical industry and expanding its product offerings.

The most recent analyst rating on (HK:3692) stock is a Buy with a HK$22.06 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.

More about Hansoh Pharmaceutical Group Company Limited

Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company incorporated in the Cayman Islands. It focuses on the development of innovative drugs, particularly in the area of hypercholesterolemia and dyslipidemia.

Average Trading Volume: 12,089,628

Technical Sentiment Signal: Buy

Current Market Cap: HK$157.9B

For a thorough assessment of 3692 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1